Beyond Air (XAIR) Company Report

Beyond Air (XAIR) is preparing for the anticipated FDA approval of its second-generation nitric oxide delivery machine before the end of 2026, which is designed to be smaller, more user-friendly, and capable of inter-hospital transport, addressing key limitations of its first-generation product and aiming for majority U.S. market share.
The company has initiated an aggressive international expansion, securing distribution partners in 40 countries within the last nine months, with the ex-U.S. market expected to be double the U.S. market in dollar value over the next 5-7 years, anticipating significant revenue impact from 2026 into 2027.
Beyond Air is advancing a diverse nitric oxide-mediated pipeline, including programs for infectious diseases (e.g., NTM lung infection), cancer (with human trial data showing a "big survival signal" to be presented in 2026), and preclinical neurological conditions.
The company reports having enough cash to reach approval for its next-generation product, with international distribution partners expected to act as a force multiplier for growth and potentially reduce the need for further capital raises.

4 days ago

Transcript

Beyond Air Details Second-Generation Product and International Growth Strategy

XAIR

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Beyond Air (XAIR) is awaiting FDA approval for its second-generation nitric oxide machine before the end of 2026, which is designed to be smaller, more user-friendly, and includes inter-hospital transport capabilities, with the company anticipating it will help secure a majority of U.S. market share.
The company has initiated international expansion, establishing distribution partnerships in 40 countries within the last nine months, and projects the ex-U.S. market to be double the U.S. market in dollar value over the next 5-7 years.
Significant revenue impact from overseas markets is expected to begin in 2026 and become substantial in 2027.
Beyond Air's pipeline includes applications of nitric oxide for infectious diseases, cancer (showing promising survival data in refractory patients), and neurological conditions such as Phelan-McDermid syndrome and glioblastoma.
The company has sufficient cash to reach approval for its next-generation product and holds patents for its LungFit machine extending to 2040, with potential for the second-generation to reach 2044.

4 days ago

Transcript

Beyond Air Highlights Product Advantages, Pipeline, and International Growth Strategy

XAIR

Product Launch

New Projects/Investments

Guidance Update

Beyond Air's nitric oxide system offers significant advantages over cylinder-based and chemical-based competitors, including safety, ease of use, and cost-effectiveness, and has secured 40 international distribution partners since spring 2025.
The company anticipates FDA approval for its second-generation device before the end of 2026, which is smaller, more user-friendly, and includes critical transport capabilities, addressing limitations of the first-generation product.
Beyond Air projects the ex-U.S. market to be double the dollar value of the U.S. market over the next 5-7 years, with significant revenue impact from international sales expected in 2027.
The company is advancing a diverse nitric oxide-mediated pipeline, including infectious disease programs, promising early human data in cancer (25,000-50,000 parts per million NO), and preclinical neurological programs, with patents extending past 2040.
Beyond Air has sufficient cash to reach approval of its next-generation product and may seek additional capital for a proper launch, while leveraging international distributors to multiply growth.

4 days ago

Transcript

Beyond Air Announces Sale of Majority Stake in NeuroNOS to XTL Biopharmaceuticals

XAIR

M&A

New Projects/Investments

XTL Biopharmaceuticals Ltd. (XTLB) entered a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (XAIR), on January 13, 2026.
As part of the transaction, Beyond Air will hold 19.99% of XTL's post-transaction share capital.
Beyond Air is also set to receive $1 million in cash and up to $31.5 million in milestone-based contingent payments, totaling up to $32.5 million.
NeuroNOS, which focuses on disease-modifying therapeutics for Autism Spectrum Disorder, has secured two FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma.

5 days ago

8-K

XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS

XAIR

M&A

New Projects/Investments

On January 13, 2026, XTL Biopharmaceuticals Ltd. announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc..
The acquisition consideration includes $1 million in cash, 19.9% of XTL's issued share capital, and milestone-based contingent payments totaling up to $32.5 million.
Beyond Air, the former majority owner of NeuroNOS, will hold 19.99% of XTL's post-transaction share capital and is eligible to receive up to $32.5 million in upfront, development, and commercial milestone payments.
NeuroNOS focuses on disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology, having secured two FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma.
This acquisition positions XTL in the autism therapeutics market, addressing a critical unmet medical need as no FDA-approved disease-modifying therapies exist for autism, and brings Nobel Prize-winning scientific leadership to XTL.

7 days ago

Press Release

Beyond Air Expands LungFit PH International Distribution Network

XAIR

Product Launch

New Projects/Investments

Beyond Air, Inc. has secured new international distribution agreements for its LungFit® PH system, adding countries such as Germany, Brazil, Austria, the Netherlands, and Sri Lanka to its network.
This expansion increases the total international coverage for LungFit PH to 39 countries, collectively representing a population exceeding three billion people.
The company anticipates that some of these new markets will begin to utilize LungFit PH in calendar 2026.
LungFit PH's tankless technology generates nitric oxide from ambient air, aiming to streamline hospital operations and improve efficiency by eliminating the need for traditional high-pressure cylinders.

Dec 17, 2025, 12:30 PM

Press Release

Beyond Air Reports Fiscal Q2 2026 Results and Updates Guidance

XAIR

Earnings

Guidance Update

Debt Issuance

Beyond Air reported Q2 2026 revenue of $1.8 million, a 128% increase year-over-year, and a net loss of ($7.9) million or ($1.25) per share for the fiscal quarter ended September 30, 2025.
The company updated its fiscal year 2026 revenue guidance to $8 - $10 million.
Beyond Air secured $12.0 million in debt financing, resulting in proforma cash, cash equivalents, restricted cash, and marketable securities of $22.9 million as of September 30, 2025. Bob Goodman was also appointed Interim Chief Commercial Officer.

Nov 14, 2025, 9:30 PM

8-K

Beyond Air Announces Q2 Fiscal Year 2026 Results and Updates Guidance

XAIR

Earnings

Guidance Update

Debt Issuance

Beyond Air reported Q2 fiscal year 2026 revenue of $1.8 million for the period ended September 30, 2025, representing a 128% increase year-over-year from $0.8 million in the same period last year, though sequential growth was flat.
The company updated its fiscal year 2026 revenue guidance to $8-$10 million.
Beyond Air secured $12 million in debt and plans to file a registration statement for an additional $20 million equity line of credit with Streeterville Capital, which is expected to provide financial runway into calendar 2027.
Operational highlights include the first international commercial placement of LungFit PH, the introduction of a capital purchase sales model in the U.S., and the appointment of Bob Goodman as interim Chief Commercial Officer.
The second-generation LungFit system is anticipated for commercial launch in the U.S. market in late calendar year 2026, pending FDA approval.

Nov 10, 2025, 9:30 PM

Transcript

Beyond Air Secures $32 Million in Financing and Reprices Stock Options

XAIR

Debt Issuance

New Projects/Investments

Executive Compensation

Beyond Air, Inc. entered into financing agreements with Streeterville Capital for up to $32 million in total potential proceeds.
This financing package includes a $12 million promissory note with a 15% annual interest rate and a 24-month maturity, and a $20 million Equity Line of Credit (ELOC) for selling common stock over a 24-month period.
The company expects this financing to extend its cash runway into calendar 2027.
On November 4, 2025, Beyond Air approved a one-time stock option repricing for 726,618 options, adjusting the exercise price to $1.95 for options previously above this amount.